Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
Open Access
- 23 March 2020
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (7), 1230-1238
- https://doi.org/10.1002/ejhf.1782
Abstract
Aims Cancer patients suffer from impaired cardiovascular function. Elevated resting heart rate (RHR) has been identified as a marker for increased long‐term mortality in cancer patients prior to the receipt of anticancer treatment. We aimed to establish whether RHR is associated with survival in treatment‐naïve cancer patients. Methods and results This prospective study enrolled 548 unselected treatment‐naïve cancer patients between 2011 and 2013. The median age of the cohort was 62 years; 40.9% were male and 32.7% had metastatic disease. Median RHR was 72 b.p.m. Most patients were in sinus rhythm (n = 507, 92.5%). Clinical heart failure was noted in 37 (6.8%) patients. RHR was not related to cancer stage (P = 0.504). Patients in the highest RHR tertile had higher levels of high‐sensitivity troponin (P = 0.003) and N‐terminal pro‐B‐type natriuretic peptide (P = 0.039). During a median follow‐up of 25 months (interquartile range: 16–32 months; range: 0–40 months), 185 (33.8%) patients died from any cause [1‐year‐mortality: 17%, 95% confidence interval (CI) 13–20%]. In univariate survival analysis, RHR predicted all‐cause mortality [crude hazard ratio (HR) for a 5 b.p.m. increase in RHR: 1.09, 95% CI 1.04–1.15; P < 0.001], and remained significantly associated with outcome after adjustment for age, gender, tumour entity, tumour stage, cardiac status and haemoglobin (adjusted HR for a 5 b.p.m. increase in RHR: 1.10, 95% CI 1.04–1.16; P < 0.001). There was no significant impact of metastatic/non‐metastatic disease state on the predictive value of RHR (P = 0.433 for interaction). In subgroup analyses, the strongest associations for RHR with mortality were observed in lung (crude HR 1.14; P = 0.007) and gastrointestinal (crude HR 1.31; P < 0.001) cancer. Conclusions Treatment‐naïve cancer patients with higher RHRs display higher levels of cardiovascular biomarkers. RHR was independently associated with all‐cause mortality, especially in lung and gastrointestinal cancers. Elevated RHR and cardiovascular biomarkers may represent early signs of incipient cardiac dysfunction.Funding Information
- Medizinische Universität Wien
This publication has 50 references indexed in Scilit:
- Prevention of liver cancer cachexia-induced cardiac wasting and heart failureEuropean Heart Journal, 2013
- Heart Rate and Risk of Cancer Death in Healthy MenPLOS ONE, 2011
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast CancerCancer Research, 2010
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006
- Cardiotoxicity Induced by Chemotherapy and Antibody TherapyAnnual Review of Medicine, 2006
- Cardiovascular Complications of Cancer TherapyCirculation, 2004
- The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study)European Heart Journal, 2000
- Heart rate and cardiovascular mortality: The Framingham studyAmerican Heart Journal, 1987